21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa
1 October 2016. Related: Conference reports.
World AIDS 21 Durban 2016
Four day a week ART: sub-optimal drug levels but few virological failures
1 October 2016. Related: Conference reports, Treatment strategies.
Large disparities in costs of antiretrovirals between low- and middle-income countries
1 October 2016. Related: Conference reports, Antiretrovirals, Treatment access.
High risk of virological failure and loss to follow up postpartum in South Africa
1 October 2016. Related: Conference reports, Pregnancy.
Birth weight and preterm delivery outcomes of vertically vs non-vertically infected HIV positive pregnant women
1 October 2016. Related: Conference reports, Pregnancy.
High death rates among HIV positive women postpartum accessing ARVs
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy.
Higher rates of eye complications in HIV positive people on ART
1 October 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.
Short reports on selected Durban posters
1 October 2016. Related: Conference reports.
21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa
1 August 2016. Related: Conference reports.
AIDS 2016: online access to conference programme
1 August 2016. Related: Conference reports.
ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms
1 August 2016. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
ZERO HIV transmissions in PARTNER study: most widely reported i-Base article
1 August 2016. Related: Conference reports, HIV prevention and transmission.
PrEP studies at AIDS 2016: includes first preclinical data with EFdA
1 August 2016. Related: Conference reports, HIV prevention and transmission.
Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study
1 August 2016. Related: Conference reports, Antiretrovirals.
Once-daily raltegravir at last available: 48 week results from ONCEMRK study
1 August 2016. Related: Conference reports, Antiretrovirals.
Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2
1 August 2016. Related: Conference reports, Antiretrovirals.
Dolutegravir is superior to boosted atazanavir in women in the ARIA study
1 August 2016. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence
1 August 2016. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission.
Sub-Saharan African countries moving quickly to recommend “Treat All”
1 August 2016. Related: Conference reports, Treatment access, Guidelines.
Efavirenz associated with suicide risk in analysis from START study
1 August 2016. Related: Conference reports, Side effects.
CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study
1 August 2016. Related: Conference reports, Treatment strategies.
Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio
1 August 2016. Related: Conference reports, Treatment strategies.
Publications launched at AIDS 2016
1 August 2016. Related: Conference reports, Other news.